Home > Resources > Company Profiles > Genentech Inc > News

Genentech Inc (DNA)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Dr.Arthur D. Levinson, Ph.D. , CEO/Chairman of the Board/Director

www.gene.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A biotechnology company which discovers, develops and manufactures pharmaceutical products to treat patients with medical needs.

Portfolio Articles

Putting a Price on Innovation
While Genentech weighs Roche's offer, the future of Big Biotech is at stake.

Jul 25 2008
Buying the Pharma Team
Offer for Genentech is part of a wave.
Jul 21 2008
Genes 'R' Us: The New Dot-Coms?
DNA tests for everything from diseases to ancestry are proliferating as a nascent industry tries to spark a revolution. Is this déjà vu all over again?
Mar 05 2008
Welcome to the Future
With a little help from Google, secretive Silicon Calley startup 23andMe is betting you’ll want to web-surf your own DNA. But is the science ready?

Oct 15 2007

See more news on this company

News Feeds

Midday Glance: Biotechnology companies AP
Oct 10 2008
Early Glance: Biotechnology companies AP
Oct 10 2008
Final Glance: Biotechnology companies AP
Oct 09 2008
Rituxan meets goal in late stage leukemia trial AP
Oct 07 2008
Avastin-Tarceva combo fails in lung cancer trial AP
Oct 06 2008
Genentech reports brain disease in Raptiva patient AP
Oct 03 2008
Sector Snap: Biotechnology AP
Sep 30 2008
Sector Snap: Biotechnology AP
Sep 29 2008
Study: Extending time of stroke drug treatment OK AP
Sep 24 2008
2 patients taking cancer drug die of liver damage AP
Sep 23 2008

Portfolio Blogs

The Trouble With Tickers
Aug 11 2008

Press Releases

Informex to Hold Global Sourcing Strategies Conference for the Pharmaceutical Industry Oct-07-2008, 04:48PM EDT
Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA Oct-06-2008, 11:15AM EDT
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer Oct-06-2008, 01:30AM EDT
Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: DISH, DNA, RT, LEA, IRM, ERES Oct-03-2008, 10:20AM EDT
Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy Oct-03-2008, 01:30AM EDT

News From Around the Web

News

Funds Benefiting from a Healthy Biotechnology IndustryÂ (Morningstar)

Oct 10 2008
Case of PML reported in efalizumab-treated patient (Modern Medicine)

Oct 10 2008
Early Glance: Biotechnology companies (Boston Globe)

Oct 10 2008
Genentech touts test of Rituxan plus chemo vs. leukemia (BizJournals)

Oct 10 2008
Biotech Cruises On Despite a Turbulent Economic Climate (BioPharm International)

Oct 10 2008
Genentech Accelerates Decline On Increased Volume (RTTNews)

Oct 09 2008
Roche Says Offer Is on Track (Wall Street Journal)

Oct 09 2008
Biotechnology companies shares mixed at the close of trading (Canadian Business Online)

Oct 08 2008
Genentech Study Failure Highlights Pitfalls of Cancer Drug Combos (Wall Street Journal Health Blog)

Oct 07 2008

Blogs

Genentech Regains "Title" As Best Biopharma Employer (CNBC: Pharmas Market with Mike Huckman)

Oct 10 2008
The Last Word--For Now--On Dendreon (CNBC: Pharmas Market with Mike Huckman)

Oct 08 2008
Option Update: Genentech volatility elevated; shares below Roche's $89 offer (Blogging Stocks)

Oct 08 2008
Roche Speaks My Language But Genentech Not So Much (CNBC: Pharmas Market with Mike Huckman)

Oct 07 2008

Employees

Number of Employees: 11,174

Revenue per Employee: $1,113,073

Top Executives

David A. Ebersman, Executive VP/CFO

Patrick Y. Yang, Ph.D., Divisional Executive VP

Richard H. Scheller, Ph.D., Divisional Executive VP

Dr. Hal Barron, M.D., F.A.C.C., Chief Medical Officer/Senior VP, Divisional

Robert L. Garnick, Ph.D., Divisional Senior VP

Ian T. Clark, Divisional Executive VP

Dr.Susan D. Desmond-Hellmann, M.D., M.P.H., Divisional President

Robert E. Andreatta, Chief Accounting Officer/Controller

John M. Whiting, Vice President, Divisional

Stephen G. Juelsgaard, D.V.M., J.D., Executive VP/Other Executive Officer/Secretary

Board of Directors

Dr. Jonathan K.C. Knowles, Ph.D., Director

Debra L. Reed, Director

Dr.Herbert W. Boyer, Ph.D., Director/Founder

Dr. Erich Hunziker, Ph.D., Director

Stephen G. Juelsgaard, D.V.M., J.D., Executive VP/Other Executive Officer/Secretary

William Matt Burns, Director

Dr.Charles A. Sanders, M.D., Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	01/2008	10/2007
Sales	441 Mil.	389 Mil.	344 Mil.	552 Mil.
Gross Operating Profit	2.8 Bil.	2.67 Bil.	2.63 Bil.	2.36 Bil.
Operating Income before D & A (EBITDA)	1.27 Bil.	1.54 Bil.	1.04 Bil.	1.2 Bil.
Total Income Before Interest Expenses (EBIT)	1.32 Bil.	1.28 Bil.	1.02 Bil.	1.15 Bil.
Total Net Income	782 Mil.	790 Mil.	632 Mil.	685 Mil.
Basic EPS, Total	0.74	0.75	0.6	0.65
Diluted EPS, Total	0.73	0.74	0.59	0.64

BALANCE STATEMENT	07/2008	04/2008	01/2008	10/2007
Cash and Equivalents	4.5 Bil.	4.86 Bil.	NA	1.7 Bil.
Total Assets	NA	NA	NA	6.67 Bil.
Total Liabilities	2.7 Bil.	3.97 Bil.	NA	2.06 Bil.
Total Capitalization	15.76 Bil.	15.37 Bil.	NA	13.98 Bil.

Cash Flow	07/2008	04/2008	01/2008	10/2007
Net Cash From Continuing Operations	NA	NA	NA	2.07 Bil.
Net Cash From Investing Activities	NA	NA	NA	-1.35 Bil.
Net Cash From Financing Activities	NA	NA	NA	-274 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	453 Mil.

Income Statement	2008	2007	2006	2005
Sales	1.57 Bil.	774 Mil.	640.9 Mil.	319.3 Mil.
Gross Operating Profit	10.15 Bil.	8.51 Bil.	5.99 Bil.	3.66 Bil.
Operating Income before D & A (EBITDA)	4.37 Bil.	4.72 Bil.	2.47 Bil.	1.03 Bil.
Total Income Before Interest Expenses (EBIT)	4.5 Bil.	3.48 Bil.	2.06 Bil.	1.23 Bil.
Total Net Income	2.77 Bil.	2.11 Bil.	1.28 Bil.	784.82 Mil.
Basic EPS, Total	2.63	2.01	1.21	0.74
Diluted EPS, Total	2.59	1.97	1.18	0.73

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	1.25 Bil.	1.23 Bil.	270.12 Mil.
Total Assets	NA	5.7 Bil.	4.42 Bil.	3.42 Bil.
Total Liabilities	NA	2.16 Bil.	1.66 Bil.	1.24 Bil.
Total Capitalization	NA	11.68 Bil.	9.55 Bil.	7.19 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	2.14 Bil.	2.36 Bil.	1.2 Bil.
Net Cash From Investing Activities	NA	-1.68 Bil.	-1.78 Bil.	-451.56 Mil.
Net Cash From Financing Activities	NA	-432 Mil.	367.53 Mil.	-846.31 Mil.
Net Change in Cash & Cash Equivalents	NA	25 Mil.	955.39 Mil.	-102.03 Mil.

Genentech Inc (DNA)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request